eVetPractice vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
Cloud veterinary practice management covering records, scheduling, invoicing, and pharmacy for small-animal clinics. El Segundo CA; developed by Covetrus as the cloud-native complement to legacy AVImark;
About
eVetPractice is an El Segundo, California-based cloud-based veterinary practice management software that provides independent veterinary clinics with scheduling, electronic medical records, treatment tracking, invoicing, pharmacy management, and client communication in a single web-based platform. Developed by Covetrus, eVetPractice represents the company's cloud-native veterinary practice management offering alongside its legacy AVImark on-premise system, targeting practices ready to move to a browser-based system without the hardware and IT maintenance overhead of on-premise software. The platform is designed for small-animal general practices and emergency hospitals, with clinical templates and workflows appropriate for companion animal medicine.\n\neVetPractice's pharmacy management module is a notable capability, allowing veterinary practices to manage in-clinic medication dispensing, track controlled substance logs, and connect to online pharmacy fulfillment through Covetrus's online pharmacy network. This pharmaceutical connectivity aligns with Covetrus's broader strategy of integrating its animal health distribution and pharmacy businesses with its practice management software. Practices using eVetPractice can process prescription refill requests and manage client prescription histories within the same system used for scheduling and medical records, reducing the context-switching that comes with managing separate pharmacy and practice management platforms.\n\neVetPractice competes with Shepherd, Digitail, ezyVet, and the modernized versions of legacy systems in the cloud veterinary practice management market. The company's positioning within Covetrus gives it integration advantages with the broader Covetrus ecosystem including diagnostic imaging, laboratory connectivity, and prescription management, but also means its development roadmap is influenced by the priorities of a large animal health distributor rather than solely by independent veterinary practice needs. eVetPractice serves practices primarily in the United States with a focus on the independent practice segment.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.